Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) will host an Investor Event on October 6, 2025, at 10:00 AM ET in New York City, offering both in-person and virtual attendance options. The event will showcase new data from the Phase 1b ARC-20 trial of their HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC).

The presentation will feature management team members and key opinion leaders discussing HIF-2a biology and ccRCC treatment. Additionally, Arcus will present its research in autoimmune and inflammatory diseases, with planned new IND filings in 2026 and 2027.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in three major investor conferences in September 2025:

• Citi's 2025 Biotech Back to School Conference on September 3rd in Boston at 11:15 a.m. ET
• H.C. Wainwright Global Investment Conference on September 9th in New York at 8:00 a.m. ET
• Morgan Stanley Global Healthcare Conference on September 10th in New York at 8:30 a.m. ET

All events will feature fireside chats and one-on-one meetings, with live webcasts available on the company's website.

Arcus Biosciences (NYSE:RCUS) reported Q2 2025 financial results and pipeline updates, highlighting significant progress in its oncology portfolio. The company ended the quarter with $927 million in cash, positioning it well for pipeline advancement. Key developments include the initiation of PEAK-1, a Phase 3 study of casdatifan + cabozantinib in RCC, and eVOLVE-RCC02, a Phase 1b/3 study with AstraZeneca.

Financial highlights include revenues of $160 million (up from $39M in Q2 2024), R&D expenses of $139 million, and break-even net income. The revenue increase was primarily driven by a $143 million cumulative catch-up related to etrumadenant program changes.

Clinical progress includes promising data from ARC-20 study showing 46% confirmed response rate in RCC patients, with additional data readouts expected in fall 2025 and 2026. The company anticipates R&D expenses to decline from Q4 2025 as domvanalimab Phase 3 costs decrease.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to a new employee. The package includes options to purchase 4,200 shares at an exercise price of $9.75 per share and restricted stock units (RSUs) for 2,100 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS) announced that its investigational CD73 inhibitor, quemliclustat, received orphan drug designation from the FDA for pancreatic cancer treatment. The designation provides benefits including tax credits, user fee exemptions, and potential 7-year market exclusivity upon approval.

Phase 1 ARC-8 study results showed promising median overall survival of 15.7 months with quemliclustat-based regimens, surpassing historical chemotherapy benchmarks. The company's Phase 3 PRISM-1 trial, evaluating quemliclustat plus chemotherapy in 610 first-line metastatic pancreatic cancer patients, is expected to complete enrollment by end of 2025.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to six new employees. The awards include 54,800 stock options at an exercise price of $8.50 per share and 27,550 restricted stock units (RSUs). These equity grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee approved equity awards for one new employee, including options to purchase 2,850 shares at $8.63 per share and restricted stock units for 1,450 shares. The grants were made under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The compensation package includes options to purchase 8,400 shares of common stock at $9.85 per share (the closing price on June 9, 2025) and restricted stock units for 4,200 shares. These grants were made under the company's 2020 Inducement Plan, which was established in January 2020 under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS) reported promising initial data from the ARC-20 study evaluating casdatifan (HIF-2a inhibitor) plus cabozantinib (tyrosine kinase inhibitor) in metastatic kidney cancer patients. The combination demonstrated a 46% confirmed overall response rate in patients with minimum 12-week follow-up. Among 24 efficacy-evaluable patients, 4% achieved complete response, 42% partial response, and 50% stable disease, with only 4% showing disease progression. The safety profile was manageable with no unexpected risks among 42 safety-evaluable patients. Based on these positive results, Arcus plans to initiate two key trials: PEAK-1, a Phase 3 study in immunotherapy-experienced patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line patients.